Time for Action: Investing in Health Canada
Recent data reveal a troubling trend: Health Canada is taking longer to assess generic and biosimilar drug submissions, delaying the arrival of cost-saving prescription medications on the market, and increasing costs for Canadian taxpayers and patients.
As the federal government prepares to unveil its budget on November 4, it is vital that it address these delays through strategic investments in Health Canada’s resources and staffing.
- The number and complexity of drug submissions received by Health Canada have been increasing for many years.
- Resources for its drug review programs have remained largely static and chronically underfunded.
Regulators in other countries have seen similar submission trends and made the strategic hiring investments needed to meet increased demands and maintain predictable business operations.
The issue is pressing.
Author's summary: Canada needs investments in Health Canada.
More News
- Australian government bans Dutch volleyball rapist
- Antifa Terrorism Charges: A Victory for Law Enforcement
- Park Washroom Enhancement Program
- Plans submitted for eight-tower masterplanned community in Sydney
- ZoomInfo Shares Face Reality Check Amid Impressive Rally () | aktiencheck.de
- First AI Chip That Learns and Infers
- Plans submitted for 54-storey residential tower in Canary Wharf
- ZoomInfo Shares Face Reality Check Amid Impressive Rally () | aktiencheck.de
- Time for Action: Investing in Health Canada to Accelerate Access to…
- The War on Plastic is Protracted